Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma

被引:23
作者
Turanli, Beste [1 ,2 ]
Gulfidan, Gizem [1 ]
Arga, Kazim Yalcin [1 ]
机构
[1] Marmara Univ, Dept Bioengn, Istanbul, Turkey
[2] Istanbul Medeniyet Univ, Dept Bioengn, Istanbul, Turkey
关键词
systems biomedicine; transcriptomics; drug repositioning; gene-by-drug interactions; pharmacogenomics; MIFEPRISTONE RU486; SIGNATURES; DISCOVERY; TARGETS; CANCER;
D O I
10.1089/omi.2017.0127
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Drug repositioning is an innovative approach to identify new therapeutic indications for existing drugs. Drug repositioning offers the promise of reducing drug development timeframes and costs, and because it involves drugs that are already in the clinic, it might remedy some of the drug safety challenges traditionally associated with drug candidates that are not yet available in the clinic. The gene-by-drug interactions are an important dimension of optimal drug repositioning and development strategies. While gene-by-drug interactions have been curated and presented in various databases, novel bioinformatics tools and approaches are timely, and required with a specific focus to support drug positioning. We report, in this study, the design of a public web-accessible transcriptomic-/gene expression-guided pharmaceuticals search tool, geneXpharma (www.genexpharma.org). GeneXpharma is a public platform with user-centric interface that provides statistically evaluated gene expressions and their drug interactions for 48 diseases under seven different disease categories. GeneXpharma is designed and organized to generate hypotheses on druggable genome within the disease-gene-drug triad and thus, help repositioning of drugs against diseases. The search system accommodates various entry points using drugs, genes, or diseases, which then enable researchers to extract drug repurposing candidates and readily export for further evaluation. Future developments aim to improve the geneXpharma algorithm, enrich its content, and enhance the website interface through addition of network visualizations and graphical display items. Bioinformatics search tools can help enable the convergence of drug repositioning and gene-by-drug interactions so as to further optimize drug development efforts in the future.
引用
收藏
页码:584 / 591
页数:8
相关论文
共 26 条
[1]   Integrated analysis of numerous heterogeneous gene expression profiles for detecting robust disease-specific biomarkers and proposing drug targets [J].
Amar, David ;
Hait, Tom ;
Izraeli, Shai ;
Shamir, Ron .
NUCLEIC ACIDS RESEARCH, 2015, 43 (16) :7779-7789
[2]   DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information [J].
Amelio, I. ;
Gostev, M. ;
Knight, R. A. ;
Willis, A. E. ;
Melino, G. ;
Antonov, A. V. .
CELL DEATH & DISEASE, 2014, 5 :e1051-e1051
[3]   NCBI GEO: archive for functional genomics data sets-update [J].
Barrett, Tanya ;
Wilhite, Stephen E. ;
Ledoux, Pierre ;
Evangelista, Carlos ;
Kim, Irene F. ;
Tomashevsky, Maxim ;
Marshall, Kimberly A. ;
Phillippy, Katherine H. ;
Sherman, Patti M. ;
Holko, Michelle ;
Yefanov, Andrey ;
Lee, Hyeseung ;
Zhang, Naigong ;
Robertson, Cynthia L. ;
Serova, Nadezhda ;
Davis, Sean ;
Soboleva, Alexandra .
NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) :D991-D995
[4]   A comparison of normalization methods for high density oligonucleotide array data based on variance and bias [J].
Bolstad, BM ;
Irizarry, RA ;
Åstrand, M ;
Speed, TP .
BIOINFORMATICS, 2003, 19 (02) :185-193
[5]   A standard database for drug repositioning [J].
Brown, Adam S. ;
Patel, Chirag J. .
SCIENTIFIC DATA, 2017, 4
[6]   Natural progression of diabetic peripheral neuropathy in the Zenarestat study population [J].
Brown, MJ ;
Bird, SJ ;
Watling, S ;
Kaleta, H ;
Hayes, L ;
Eckert, S ;
Foyt, HL .
DIABETES CARE, 2004, 27 (05) :1153-1159
[7]   Tissue-Specific Molecular Biomarker Signatures of Type 2 Diabetes: An Integrative Analysis of Transcriptomics and Protein-Protein Interaction Data [J].
Calimlioglu, Beste ;
Karagoz, Kubra ;
Sevimoglu, Tuba ;
Kilic, Elif ;
Gov, Esra ;
Arga, Kazim Yalcin .
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2015, 19 (09) :563-573
[8]   Drug repurposing from the perspective of pharmaceutical companies [J].
Cha, Y. ;
Erez, T. ;
Reynolds, I. J. ;
Kumar, D. ;
Ross, J. ;
Koytiger, G. ;
Kusko, R. ;
Zeskind, B. ;
Risso, S. ;
Kagan, E. ;
Papapetropoulos, S. ;
Grossman, I. ;
Laifenfeld, D. .
BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (02) :168-180
[9]   The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis [J].
Chen, Jianzhong ;
Wang, Jichuang ;
Shao, Jingwei ;
Gao, Yu ;
Xu, Jianguo ;
Yu, Suhong ;
Liu, Zhenhua ;
Jia, Lee .
MEDICINAL RESEARCH REVIEWS, 2014, 34 (05) :979-1000
[10]  
Deotarse P.P., 2015, INT J PHARM RES REV, V4, P51